Recombinant Mouse Melatonin receptor type 1A (Mtnr1a)

What are the key pharmacological differences between recombinant mouse MT1 and MT2 receptors?

How can I validate the expression of recombinant mouse MT1 receptors in my experimental system?

Validating MT1 receptor expression requires a multi-faceted approach. The development of monoclonal antibodies has significantly improved detection capabilities. The first recommendation is to employ both molecular and protein-based detection methods:

• RT-PCR and Real-time qPCR: Use validated primer pairs targeting the Mtnr1a gene. RNA samples should include appropriate controls, with PCR reactions performed using 400 ng RNA for MT1 (40 cycles) . Negative controls must include no-RT controls to ensure amplicons result only from reversely transcribed mRNA.

• Western blotting: Use specific antibodies such as the rabbit polyclonal anti-MT1 antibody directed against the third intracellular loop (residues 223-236: (C)RVKPDNKPKLKPQD) of mouse MT1 . Always include a blocking peptide control to confirm specificity.

• Immunofluorescence microscopy: Apply antibodies at 1:50 dilution in blocking buffer with overnight incubation at 4°C. Secondary antibodies (e.g., goat anti-rabbit-IgG conjugated to AlexaFluor 647) should be applied at 1:2,000 dilution .

• Functional assays: Measure MT1-mediated inhibition of forskolin-stimulated cAMP accumulation, which produces concentration-dependent responses with pIC50 values around 9.5-9.7 .

What are the recommended experimental conditions for studying recombinant mouse MT1 receptor signaling?

For robust experimental design when studying mouse MT1 receptor signaling:

• Cell culture systems: Chinese hamster ovary (CHO) cells provide a reliable expression system. Maintain stable transfectants in appropriate selection medium.

• Binding assays: Use [³H]-melatonin for receptor binding studies with concentrations ranging from 10 pM to 10 nM. For mouse MT1, expect pKD values around 9.89 with Bmax values of approximately 1.20 pmol/mg protein .

• Signaling assessment:

  • For G protein-mediated signaling, forskolin-stimulated cAMP assays remain the gold standard

  • Pretreat cells with pertussis toxin (100-200 ng/ml, 16-24h) to confirm Gi/Go involvement

  • Measure ERK1/2 and PI3K/AKT pathway activation as additional readouts

• Pharmacological tools:

  • Selective antagonist: Use 4P-PDOT at concentrations >100-fold higher than required for MT2 antagonism

  • Non-selective antagonist: Luzindole can be used at concentrations yielding a pA2 value of 5.75

How can heteromerization between mouse MT1 and MT2 receptors be detected in experimental systems?

Heteromerization between MT1 and MT2 receptors represents an important regulatory mechanism. To detect and validate MT1/MT2 heteromer formation:

• Co-immunoprecipitation: Use specific antibodies against each receptor subtype to pull down protein complexes. Recent studies employed this approach to demonstrate MT1/MT2 heteromer formation in mouse retina .

• Proximity Ligation Assay (PLA): This technique allows visualization of protein interactions in situ with high specificity. PLA has successfully demonstrated MT1/MT2 heteromerization in photoreceptor cells .

• Bioluminescence/Fluorescence Resonance Energy Transfer (BRET/FRET): These approaches require tagging receptors with appropriate donor/acceptor pairs.

• Functional studies: MT1/MT2 heteromers display unique pharmacological properties. For example, while low doses of the MT2-selective agonist IIK7 fail to mimic melatonin effects, higher doses activating both MT2 and MT1 protomers fully recapitulate melatonin's actions .

• Heteromer-selective compounds: The antagonists 4P-PDOT and luzindole show activity against MT1/MT2 heteromers that differs from their action on homomers.

Experimental validation should include knockout controls (MT1-/- or MT2-/- mice) or dominant negative mutants to confirm heteromer-specific effects.

What approaches can resolve contradictory findings regarding MT1 receptor distribution in mouse tissues?

Resolving contradictory findings regarding MT1 receptor distribution requires rigorous methodology:

• Multiple detection techniques: Implement complementary approaches including in situ hybridization, RT-PCR, and immunohistochemistry. Recent studies demonstrated MT1 expression in mouse mesenteric artery smooth muscle but not in rat vessels using this multi-method approach .

• Knockout controls: All detection methods should include tissues from MT1-/- mice as negative controls. This practice was instrumental in validating monoclonal antibody specificity in studies examining MT1 expression in retina, suprachiasmatic nuclei, and pituitary gland .

• Quantitative expression analysis: Real-time qPCR provides quantitative comparison between tissues. When comparing MT1 gene expression, use the 2^-ΔΔCt method with appropriate housekeeping genes like β-actin (ACTB) .

• Antibody validation: Address the historical challenge of unreliable antibodies by using extensively characterized monoclonal antibodies. Specificity should be confirmed through Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assays .

• Species differences: Note that antibody cross-reactivity varies significantly between species. For example, some monoclonal antibodies specific for mouse MT1 show no cross-reactivity with rat MT1 , potentially explaining some contradictory findings.

How do mutations in the mouse Mtnr1a gene affect receptor function and physiological outcomes?

Mutations in the mouse Mtnr1a gene produce complex phenotypes that reveal critical insights into receptor function:

• Knockout models: Complete MT1 receptor deletion (MT1-/-) has demonstrated that:

  • MT1 mediates melatonin's inhibitory effects on suprachiasmatic nucleus (SCN) neuronal firing

  • MT1 is essential for rapid eye movement (REM) phase regulation during sleep

  • MT1 deletion affects glucose homeostasis, supporting its role in metabolic regulation

• Point mutations and partial deletions: CRISPR/Cas9-mediated deletion mutations in the Mtnr1a gene revealed unexpected findings, including that heterozygous mutations can sometimes produce more severe phenotypes than homozygous deletions. In Xenopus tropicalis, heterozygous Mtnr1a mutations caused rod photoreceptor loss, while homozygous mutants were less affected .

• Signaling consequences: Mutations can differentially impact various signaling pathways:

  • cAMP inhibition via Gi/Go proteins

  • ERK1/2 pathway activation

  • PI3K/AKT signaling

  • PLC-PKC pathway modulation

• Tissue-specific effects: The consequence of Mtnr1a mutations varies by tissue. For example, in vascular tissues, MT1 receptor mutations can affect neurogenic contractions in mesenteric arteries through PVAT-dependent mechanisms .

• Developmental timing: Some phenotypes of MT1 mutations are age-dependent. Rod photoreceptor degeneration in Mtnr1a mutants was evident during development but less obvious after metamorphosis .

What are the optimal conditions for expressing functional recombinant mouse MT1 receptors in heterologous systems?

For optimal expression of functional recombinant mouse MT1 receptors:

• Expression systems:

  • CHO cells demonstrate reliable expression and appropriate post-translational modifications

  • HEK293 cells are suitable for transient expression studies

  • Avoid systems with endogenous melatonin receptor expression

• Vector selection:

  • Use mammalian expression vectors with strong promoters (CMV, EF1α)

  • Consider vectors with inducible expression systems for receptors that might exhibit constitutive activity

  • Include appropriate tags (His, FLAG) that don't interfere with receptor function

• Transfection optimization:

  • For stable expression, linearize plasmid DNA before transfection

  • Optimize transfection reagent:DNA ratios (typically 3:1 for lipid-based transfection)

  • Allow 48-72 hours post-transfection before testing expression

• Selection strategy:

  • For stable lines, use appropriate antibiotic selection (G418 at 400-800 μg/ml)

  • Consider fluorescence-activated cell sorting for homogeneous populations

  • Test multiple clones to identify those with physiological expression levels

• Expression validation:

  • Verify protein expression by Western blot

  • Confirm membrane localization through subcellular fractionation

  • Assess functionality through binding assays using [³H]-melatonin

How can I design experiments to differentiate between MT1 monomer, homodimer, and heterodimer signaling?

Designing experiments to distinguish between different MT1 receptor configurations requires sophisticated approaches:

• Pharmacological differentiation:

  • MT1/MT2 heterodimers display distinct pharmacological profiles from monomers/homodimers

  • Use the MT2-selective agonist IIK7 at varying concentrations: low doses activate only MT2 protomers, while higher doses can activate both MT1 and MT2 in heteromeric complexes

  • MT1/MT2 heteromers are antagonized by 4P-PDOT and luzindole with distinct potencies

• Biophysical approaches:

  • Implement BRET/FRET with differentially tagged receptors

  • For monomers vs. homodimers, use constructs with the same receptor but different tags

  • For heterodimers, tag MT1 and MT2 with compatible donor/acceptor pairs

• Genetic manipulation:

  • Express dominant negative mutants to disrupt specific receptor configurations

  • Use CRISPR/Cas9 to create cell lines lacking one receptor type

  • Implement controlled expression systems with titrated receptor ratios

• Signaling readouts:

  • Different receptor configurations preferentially couple to distinct signaling pathways

  • Measure multiple pathways simultaneously (cAMP, Ca²⁺, ERK1/2, β-arrestin recruitment)

  • Compare signaling kinetics, as dimers may show altered activation/deactivation profiles

• Spatial organization:

  • Use super-resolution microscopy to visualize receptor clustering

  • Implement single-particle tracking to assess mobility differences between configurations

  • Apply mathematical modeling to differentiate between configurations based on mobility data

What are the most reliable methods for quantifying recombinant mouse MT1 receptor expression levels?

Reliable quantification of recombinant mouse MT1 receptor expression requires complementary approaches:

• Ligand binding assays:

  • Saturation binding with [³H]-melatonin remains the gold standard

  • Calculate Bmax values to determine receptor density (pmol/mg protein)

  • Expect Bmax values around 1.20 pmol/mg protein for MT1 receptors in CHO cells

  • Include non-specific binding controls using excess unlabeled melatonin (10 μM)

• Western blot quantification:

  • Use validated antibodies against MT1 (e.g., rabbit polyclonal anti-MT1)

  • Include calibration curves with recombinant protein standards

  • Normalize to housekeeping proteins and total protein loading

  • Use fluorescent secondary antibodies for wider linear detection range

• Flow cytometry:

  • Apply cell-surface labeling with non-permeabilized cells

  • Use fluorophore-conjugated antibodies or primary/secondary combinations

  • Include calibration beads with known antibody binding capacity

  • Express results as molecules of equivalent soluble fluorochrome (MESF)

• RT-qPCR:

  • Implement absolute quantification with plasmid standards

  • Include multiple reference genes for normalization

  • Convert to copy number per cell using appropriate calculations

  • Note that mRNA levels may not directly correlate with protein expression

• Mass spectrometry:

  • Apply targeted proteomics with isotope-labeled peptide standards

  • Focus on unique peptides from the MT1 sequence

  • Implement parallel reaction monitoring for improved sensitivity

  • Express results as fmol receptor per mg total protein

How can biased signaling at recombinant mouse MT1 receptors be assessed and exploited in experimental systems?

Biased signaling at MT1 receptors represents an exciting research frontier:

• Multipathway profiling:

  • Systematically measure multiple signaling outputs including:

    • Gi/Go-mediated cAMP inhibition

    • ERK1/2 and PI3K/AKT pathway activation

    • β-arrestin recruitment

    • Receptor internalization kinetics

  • Calculate bias factors using operational models comparing pathway activation relative to a reference ligand (typically melatonin)

• Biased ligand identification:

  • Screen compound libraries against different signaling pathways

  • Recent studies identified compound 37 as devoid of Gi signaling at MT1 while maintaining other activities

  • Test novel synthetic MT1 agonists for differential pathway activation

• Pathway inhibitor toolkit:

  • Use pertussis toxin (100-200 ng/ml) to block Gi/Go signaling

  • Apply PD98059 or U0126 to inhibit MEK/ERK pathway

  • Implement PI3K inhibitors like wortmannin or LY294002

  • Use β-arrestin siRNA knockdown or CRISPR knockout

• Structural determinants:

  • Implement site-directed mutagenesis of key residues in transmembrane domains and intracellular loops

  • Focus particularly on the third intracellular loop (residues 223-236), which contains important G protein coupling determinants

  • Create receptor chimeras with domains from MT1 and MT2 to identify regions critical for pathway selectivity

• Physiological correlates:

  • Correlate biased signaling profiles with specific physiological outcomes

  • Design in vivo studies to test whether biased MT1 agonists produce subset of melatonin effects

What role do post-translational modifications play in regulating recombinant mouse MT1 receptor function?

Post-translational modifications of MT1 receptors represent an under-explored regulatory mechanism:

• Phosphorylation sites:

  • Multiple serine and threonine residues in the C-terminal tail and third intracellular loop can undergo phosphorylation

  • Use phosphosite-specific antibodies or mass spectrometry to identify phosphorylation patterns

  • Implement site-directed mutagenesis (S/T→A) to prevent phosphorylation at specific sites

  • Assess how phosphorylation affects G protein coupling, arrestin recruitment, and internalization

• Glycosylation:

  • N-linked glycosylation occurs at asparagine residues in the N-terminal domain

  • Treat cells with tunicamycin to inhibit N-glycosylation or use PNGase F enzymatically

  • Create glycosylation-deficient mutants to assess importance for trafficking and ligand binding

  • Determine if species differences in glycosylation contribute to pharmacological differences

• Palmitoylation:

  • Cysteine residues in the C-terminal tail can undergo palmitoylation

  • Use click chemistry with alkyne-tagged palmitate analogs to detect palmitoylation

  • Apply 2-bromopalmitate to inhibit palmitoylation

  • Assess consequences for receptor localization in membrane microdomains

• Ubiquitination:

  • Lysine residues can be modified with ubiquitin, targeting receptors for degradation

  • Use proteasome inhibitors (MG132) to block degradation

  • Immunoprecipitate receptors and probe for ubiquitin to assess modification

  • Determine if chronic agonist exposure leads to increased ubiquitination

• Methodological approach:

  • Combined immunoprecipitation/mass spectrometry to identify all modifications

  • Create a comprehensive map of MT1 modifications under basal and stimulated conditions

  • Determine tissue-specific modification patterns using recombinant expression in different cell types

How can advances in structural biology be applied to the study of recombinant mouse MT1 receptors?

Recent structural biology advances offer unprecedented opportunities for MT1 receptor research:

• Cryo-electron microscopy (cryo-EM):

  • Generate stable MT1 receptor complexes with G proteins or other signaling partners

  • Implement antibody fragments or nanobodies to stabilize specific conformations

  • Determine structural differences between active and inactive states

  • Recent XFEL studies of human MT1/MT2 receptors provide templates for mouse receptor modeling

• Molecular dynamics simulations:

  • Build models of mouse MT1 receptors based on human structures

  • Simulate ligand binding and conformational changes during activation

  • Identify species-specific differences in binding pocket architecture

  • Calculate binding energies for selective ligands to explain pharmacological profiles

• Structure-based virtual screening:

  • Use high-resolution structures to screen for novel MT1-selective ligands

  • Focus on unique features of the mouse MT1 binding pocket

  • Recent virtual screening of MT structures yielded 10 new agonist chemotypes with sub-micromolar potency

  • Implement flexible docking to account for induced-fit effects

• Structural basis of biased signaling:

  • Compare structures of MT1 with different ligands to identify conformational signatures of bias

  • Focus on intracellular loop conformations that preferentially engage specific signaling partners

  • Design MT1 mutants to test structure-based hypotheses about signaling bias

• Heterodimer structures:

  • Model MT1/MT2 heterodimer interfaces

  • Identify key residues for heterodimer formation

  • Design peptides or small molecules to disrupt or stabilize specific heteromeric interfaces

  • Compare signaling from monomeric, homodimeric, and heterodimeric structures